Enovix develops lithium-ion batteries with a silicon anode built on a 3D architecture, aimed at smartphones, smart glasses and other devices where energy density matters. It also makes conventional graphite cells, including through Routejade, a South Korean battery maker it acquired in 2023, and its revenue now comes largely from a few defense-sector customers. The 10-Q says one South Korean defense subcontractor accounted for the majority of revenue in the quarter.
That split shaped the quarter. The defense and drone business grew and lifted margins, while the smartphone program that had been the company’s headline goal hit a setback: the cells passed internal qualification, but on an older process that misses the latest energy-density target. Under an interim CEO appointed in August, Enovix is now narrowing its focus and cutting costs. The sections below cover the results, the strategic change and the capital actions taken after the quarter.
Enovix Q3 2026 results at a glance
| $ millions, except per share and % | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Revenue | 11.0 | 9.0 | 8.0 |
| GAAP gross margin | 30.1% | 14.4% | 17.5% |
| Non-GAAP gross margin | 34.5% | 19.9% | 21.0% |
| GAAP loss from operations | (39.3) | (43.3) | (47.0) |
| Non-GAAP loss from operations | (29.2) | (28.8) | (29.8) |
| Net loss attributable to Enovix | (41.9) | (43.1) | (53.7) |
| Diluted net loss per share | $(0.19) | $(0.20) | $(0.27) |
Revenue and margin: drones and defense
Revenue of $11.0 million rose 38% from a year earlier and 22% from the second quarter, above the $9.0–10.0 million Enovix had guided in August, and the company calls it its sixth consecutive quarter of year-over-year revenue growth. Gross margin rose sharply: GAAP 30.1% against 17.5%, and non-GAAP 34.5% against 21.0%, which the release attributes to a richer mix including smart eyewear and drone and defense revenue.
The company’s drone, defense and industrial pipeline, which it defines as identified prospects through design wins, grew 18% to about $216 million from $183 million, with drones about $150 million of it. Orders announced with the results included an initial 100,000-battery purchase order for conventional cells from a dual-use drone systems provider and a first production order for its new MX1-B01 high-energy drone cell, whose initial deliveries are scheduled for early 2027.
Smartphone tests dropped, eyewear delayed
The AI-1 smartphone cells passed internal cell-level qualification, and the lead smartphone customer was expected to finish its parallel qualification the week after the release. But the qualification used a process from before the company’s AI-2 version, and the cells did not meet the latest energy-density target of more than 1,000 watt-hours per liter. Enovix has decided not to proceed with system-level field testing using those units, has reduced AI-1 smartphone development spending and is concentrating silicon-anode development on smaller cells for smart eyewear. The 10-Q says smartphones remain a long-term opportunity that the company expects to re-engage with when its next-generation cells restore a clear energy-density advantage.
Smart eyewear has slipped too. Enovix shipped about 8,600 AI-1 batteries in the quarter under a 50,000-pack order, below its expectations because of a manufacturing process excursion for which it says it has taken corrective action, and it now expects to complete the order in the first half of 2027 rather than in the fourth quarter of 2026, per the 10-Q. The release puts year-to-date eyewear shipments at about 19,000 units as of the release date. AI-2 cells will go first to a group of its 24 smart-eyewear customers.
That is a change from the second-quarter release, in which the then CEO said one final accelerated cycle-life test remained on the path to smartphone qualification. The 10-Q says the former CEO resigned in August 2026 and the CFO, Ryan Benton, became interim CEO.
Costs and cash
The GAAP loss from operations narrowed to $39.3 million from $47.0 million, mostly because stock compensation and other non-GAAP items fell to $10.1 million from $17.1 million; the non-GAAP operating loss of $29.2 million was within the $29.0–32.0 million guided. Net loss attributable to Enovix was $41.9 million, or $0.19 per share, with $6.6 million of interest expense against $4.9 million of interest income. Operating cash flow was negative $29.2 million, capital expenditure $3.9 million and free cash flow negative $33.1 million.
Cash, cash equivalents, marketable securities and restricted cash were $512.2 million at October 4, after $6.2 million of share repurchases in the quarter. Long-term debt, net of issuance costs, was $521.9 million; principal outstanding was $172.5 million of 2028 and $360.0 million of 2030 convertible notes.
After the quarter: notes, buybacks, warrants and layoffs
- Debt retired at a discount. Enovix repurchased $128.0 million face value of 2030 notes for about $81.4 million, a 36% discount, leaving $232.0 million of 2030 notes.
- More buybacks. Another $15.5 million of common stock was repurchased in October.
- A warrant dividend. One warrant for every four shares, exercisable at $3.00 in cash or in 2028 notes at face value, expiring April 28, 2028 at the latest; holders of the 2028 and 2030 notes receive warrants on an as-converted basis.
- Restructuring. In November Enovix began eliminating about 220 of 946 employee and contract direct-labor positions, mainly in Malaysia, for annualized savings of about $8.5 million, with a charge of about $1.5 million in the fourth quarter. The release says resources will shift toward its operations in South Korea.
Guidance: a weaker Q4, then a much larger 2027
- Q4 2026: revenue of $9.0–10.0 million, down 12–20% from $11.3 million a year earlier; non-GAAP loss from operations of $28.0–31.0 million; non-GAAP net loss per share of $0.13–0.17; capital expenditure of $5.0–8.0 million.
- Full-year 2027: revenue of $65–85 million, against the company’s own $36.7–37.7 million estimate for 2026, growth the release calculates as +75% to +128%. The interim CEO says nearly half of the midpoint is already in backlog.
What to watch in Q4
- Whether Q4 revenue lands in the $9.0–10.0 million range, below Q3’s $11.0 million.
- Conversion of the drone pipeline of about $216 million into orders, including MX1-B01 deliveries in early 2027.
- Smart-eyewear deliveries against the 50,000-pack order and AI-2 sampling.
- The warrant exercise, which can bring in cash or retire 2028 notes, and the effect of the restructuring on operating expenses.
Quick answers
What was Enovix’s revenue in Q3 2026?
$11.0 million for the fiscal quarter ended October 4, 2026, up 38% from $8.0 million a year earlier and above the company’s $9.0–10.0 million guidance.
Is Enovix still pursuing smartphones?
Enovix decided not to proceed with system-level field testing of its current smartphone cells, which did not meet its latest energy-density target, and is concentrating silicon-anode development on smart eyewear first.
What is Enovix’s 2027 revenue guidance?
$65–85 million for full-year 2027. For Q4 2026 it guides revenue of $9.0–10.0 million.
Sources and method. GAAP and non-GAAP results, the balance sheet, cash flows, the business update, the smartphone decision, the capital actions and the Q4 2026 and FY2027 guidance are Enovix’s own disclosures in Exhibit 99.1 to the Form 8-K filed 2026-11-12 (accession 0001828318-26-000069) for the fiscal quarter ended 2026-10-04, read directly from SEC EDGAR and linked above. The restructuring detail, the CEO change, customer concentration and the convertible notes outstanding are from the Form 10-Q filed 2026-11-13 (accession 0001828318-26-000072). Q3 guidance, second-quarter comparatives and the earlier smartphone wording are from the Q2 2026 Form 8-K (accession 0001828318-26-000055). The 8-K was accepted at 07:44 ET on 2026-11-12, before the open; the call was held at 1:00 p.m. ET that day. Enovix’s fiscal quarters end on a Sunday, so its third quarter ended October 4.
No consensus estimate is included, so this piece makes no claim that the quarter beat or missed expectations; “above guidance” refers only to Enovix’s own Q3 guidance from August. This piece makes no claim about the share-price reaction.
Our arithmetic, labelled as such: none beyond restating the release’s own figures; all growth rates, margin changes, the 36% discount, the remaining $232.0 million of 2030 notes and the 2027 growth range are as printed by the company. The interpretation — that drone and defense demand now drives the business while the silicon-anode program narrows to smart eyewear — is our analysis, not a company statement, and is not a forecast.
Related: Enovix Q2 2026, the prior quarter.
How exposed is your portfolio to this?
Tradune shows what you actually hold across every account — concentration, correlation between your biggest positions, and how each one has done against a buy-and-hold SPY twin funded on your own dates.
Free for everyone right now · no card · nothing to buy
Sources
- Enovix Corporation — Q3 2026 financial results and shareholder letter — Form 8-K (Items 2.02, 9.01), Exhibit 99.1 for the fiscal quarter ended 2026-10-04, filed 2026-11-12 (SEC EDGAR, CIK 0001828318, accession 0001828318-26-000069) — GAAP and non-GAAP results, balance sheet, cash flows, business update, capital actions and Q4 2026 and FY2027 guidance
- Enovix Corporation — Form 10-Q for the fiscal quarter ended 2026-10-04, filed 2026-11-13 (SEC EDGAR, accession 0001828318-26-000072) — the November restructuring, the CEO change, customer concentration and convertible notes outstanding
- Enovix Corporation — Q2 2026 financial results — Form 8-K, Exhibit 99.1 for the fiscal quarter ended 2026-07-05, filed 2026-08-12 (SEC EDGAR, accession 0001828318-26-000055) — Q3 2026 guidance, second-quarter comparatives and the earlier smartphone outlook
- Enovix Corporation — Form 8-K filing index, accession 0001828318-26-000069, filed 2026-11-12 (SEC EDGAR) — 07:44 ET acceptance time
This analysis summarizes results a company reported publicly, together with our own arithmetic on those reported figures. It is descriptive and educational — not a rating, a price target, a recommendation, or investment advice. Tradune is not a registered investment adviser.
Company financials are taken from the results release and related SEC filings; amended or final filings may revise them. Consensus estimates come from the named reports listed above and are not company-published data. Past results do not predict future returns.